Sodium–glucose linked transporter 2 inhibitors in liver cirrhosis: Beyond their antidiabetic use
Liver International · 2024-04 · 44 (4) · 884-893
DOI: 10.1111/liv.15851 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Liver International, online erschienen am 31.01.2024. Verfasst von Christos Siafarikas und 5 weiteren Autor:innen. Beteiligte Einrichtung: 1st Propaedeutic Department of Internal Medicine, Medical School of National and Kapodistrian University of Athens, General Hospital of Athens "Laiko…. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Heart Failure. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Type 2 diabetes mellitus (T2DM) and liver cirrhosis are clinical entities that frequently coexist, but glucose‐lowering medication options are limited in cirrhotic patients. Sodium–glucose linked transporter 2 (SGLT2) inhibitors are a class of glucose‐lowering medication that act independently of insulin, by causing glycosuria in the proximal convoluted tubule. In this review, we aimed to briefly present the main data and to provide insight into the pathophysiology and potential usefulness of SGLT2 inhibitors in cirrhotic patients with or without T2DM. SGLT2 inhibitors have been proven useful as antidiabetic treatment in patients with metabolic liver disease, with most robust data from patients with metabolic dysfunction‐associated steatotic liver disease (MASLD), where they also showed improvement in liver function parameters. Moreover, it has been suggested that SGLT2 inhibitors may have effects beyond their antidiabetic action. Accordingly, they have exhibited cardioprotective effects, expanding their indication in patients with heart failure without T2DM. Since decompensated liver cirrhosis and congestive heart failure share common pathophysiological features, namely renin–angiotensin–aldosterone axis and sympathetic nervous system activation as well as vasopressin secretion, SGLT2 inhibitors could also be beneficial in patients with decompensated cirrhosis, even in the absence of T2DM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- 1st Propaedeutic Department of Internal Medicine, Medical School of National and Kapodistrian University of Athens, General Hospital of Athens "Laiko", Athens, Greece.
- Heart Failure and Heart Transplantation Unit, Onassis Cardiac Surgery Center, Athens, Greece.
- Department of Gastroenterology, Medical School of National and Kapodistrian University of Athens, General Hospital of Athens "Laiko", Athens, Greece.
ORCID-Profile: Margarita Papatheodoridi, John Vlachogiannakos, George Papatheodoridis
Zitieren
APA
Siafarikas, C., Kapelios, C. J., Papatheodoridi, M., Vlachogiannakos, J., Tentolouris, N., & Papatheodoridis, G. (2024). Sodium–glucose linked transporter 2 inhibitors in liver cirrhosis: Beyond their antidiabetic use. Liver International, 44(4), 884-893. https://doi.org/10.1111/liv.15851
Vancouver
Siafarikas C, Kapelios CJ, Papatheodoridi M, Vlachogiannakos J, Tentolouris N, Papatheodoridis G. Sodium–glucose linked transporter 2 inhibitors in liver cirrhosis: Beyond their antidiabetic use. Liver International. 2024;44(4):884-893. doi:10.1111/liv.15851
BibTeX
@article{Siafarikas2024,
author = {Siafarikas, Christos and Kapelios, Chris J and Papatheodoridi, Margarita and Vlachogiannakos, John and Tentolouris, Nikolaos and Papatheodoridis, George},
title = {Sodium–glucose linked transporter 2 inhibitors in liver cirrhosis: Beyond their antidiabetic use},
journal = {Liver International},
year = {2024},
volume = {44},
number = {4},
pages = {884--893},
doi = {10.1111/liv.15851}
}
EUVIMED